Literature DB >> 26578701

Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs.

Julio A Urbina1, James H McKerrow2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26578701      PMCID： PMC4649243          DOI： 10.1128/AAC.01714-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  14 in total

Review 1.  Chagas disease etiology: autoimmunity or parasite persistence?

Authors:  R L Tarleton; L Zhang
Journal:  Parasitol Today       Date:  1999-03

2.  In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds.

Authors:  Adriana M C Canavaci; Juan M Bustamante; Angel M Padilla; Cecilia M Perez Brandan; Laura J Simpson; Dan Xu; Courtney L Boehlke; Rick L Tarleton
Journal:  PLoS Negl Trop Dis       Date:  2010-07-13

3.  Bioluminescent imaging of Trypanosoma cruzi infection.

Authors:  Kenneth V Hyland; Sofya H Asfaw; Cheryl L Olson; Melvin D Daniels; David M Engman
Journal:  Int J Parasitol       Date:  2008-04-25       Impact factor: 3.981

Review 4.  Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.

Authors:  Julio A Urbina
Journal:  J Eukaryot Microbiol       Date:  2014-11-13       Impact factor: 3.346

5.  New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice.

Authors:  Juan M Bustamante; Julie M Craft; Byron D Crowe; Sarah A Ketchie; Rick L Tarleton
Journal:  J Infect Dis       Date:  2013-08-14       Impact factor: 5.226

6.  Towards a paradigm shift in the treatment of chronic Chagas disease.

Authors:  R Viotti; B Alarcón de Noya; T Araujo-Jorge; M J Grijalva; F Guhl; M C López; J M Ramsey; I Ribeiro; A G Schijman; S Sosa-Estani; F Torrico; J Gascon
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

7.  Activity in vivo of anti-Trypanosoma cruzi compounds selected from a high throughput screening.

Authors:  Grasiella Andriani; Anne-Danielle C Chessler; Gilles Courtemanche; Barbara A Burleigh; Ana Rodriguez
Journal:  PLoS Negl Trop Dis       Date:  2011-08-30

8.  Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.

Authors:  Amanda Fortes Francisco; Michael D Lewis; Shiromani Jayawardhana; Martin C Taylor; Eric Chatelain; John M Kelly
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

9.  Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection.

Authors:  Michael D Lewis; Amanda Fortes Francisco; Martin C Taylor; Hollie Burrell-Saward; Alex P McLatchie; Michael A Miles; John M Kelly
Journal:  Cell Microbiol       Date:  2014-05-01       Impact factor: 3.715

10.  4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.

Authors:  Claudia M Calvet; Debora F Vieira; Jun Yong Choi; Danielle Kellar; Michael D Cameron; Jair Lage Siqueira-Neto; Jiri Gut; Jonathan B Johnston; Li Lin; Susan Khan; James H McKerrow; William R Roush; Larissa M Podust
Journal:  J Med Chem       Date:  2014-08-19       Impact factor: 7.446
View more
  4 in total

1.  Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.

Authors:  F H Guedes-da-Silva; D G J Batista; C F Da Silva; J S De Araújo; B P Pavão; M R Simões-Silva; M M Batista; K C Demarque; O C Moreira; C Britto; G I Lepesheva; M N C Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

2.  4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.

Authors:  Claudia Magalhaes Calvet; Jun Yong Choi; Diane Thomas; Brian Suzuki; Ken Hirata; Sharon Lostracco-Johnson; Liliane Batista de Mesquita; Alanderson Nogueira; Marcelo Meuser-Batista; Tatiana Araujo Silva; Jair Lage Siqueira-Neto; William R Roush; Mirian Claudia de Souza Pereira; James H McKerrow; Larissa M Podust
Journal:  PLoS Negl Trop Dis       Date:  2017-12-27

3.  Anti-trypanosomal activity of non-peptidic nitrile-based cysteine protease inhibitors.

Authors:  Antonio C B Burtoloso; Sérgio de Albuquerque; Mark Furber; Juliana C Gomes; Cristiana Gonçalez; Peter W Kenny; Andrei Leitão; Carlos A Montanari; José Carlos Quilles; Jean F R Ribeiro; Josmar R Rocha
Journal:  PLoS Negl Trop Dis       Date:  2017-02-21

4.  Long term follow-up of Trypanosoma cruzi infection and Chagas disease manifestations in mice treated with benznidazole or posaconazole.

Authors:  Claudia Magalhães Calvet; Tatiana Araújo Silva; Diane Thomas; Brian Suzuki; Ken Hirata; Jair Lage Siqueira-Neto; James H McKerrow
Journal:  PLoS Negl Trop Dis       Date:  2020-09-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.